PE20010681A1 - Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico - Google Patents

Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico

Info

Publication number
PE20010681A1
PE20010681A1 PE2000001083A PE0010832000A PE20010681A1 PE 20010681 A1 PE20010681 A1 PE 20010681A1 PE 2000001083 A PE2000001083 A PE 2000001083A PE 0010832000 A PE0010832000 A PE 0010832000A PE 20010681 A1 PE20010681 A1 PE 20010681A1
Authority
PE
Peru
Prior art keywords
halogen
alcoxyl
haloalkyl
alkyl
glutamate receptor
Prior art date
Application number
PE2000001083A
Other languages
English (en)
Inventor
Alexander Alanine
Vincent Mutel
Geo Adam
Erwin Goetschi
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010681A1 publication Critical patent/PE20010681A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS BENZODIAZEPIN DE FORMULA I, CUANDO X ES UN ENLACE; R1 ES HALOGENO, FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO, HALOALQUILO, ALCOXILO, HALO-ALCOXILO; CUANDO X ES ETINODIILO, R1 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO, HALOALQUILO, ALCOXILO, ENTRE OTROS; R2 ES HALOGENO, OH, ALQUILO, HALOALQUILO, ALCOXILO, HIDROXIMETILO, ENTRE OTROS; R3 ES ARILO, HETEROARILO DE 5-6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON HALOGENO, CIANO, NITRO, AZIDO, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 3-(8-CLORO-4-OXO-7-FENILETINIL-4,5-DIHIDRO-3H-BENZO[b][1,4]DIAZEPIN-2-IL)-BENZONITRILO, 3-[8-(4-METIL-PIPERAZIN-1-IL)-4-OXO-7-FENILETINIL-4,5-DIHIDRO-3H-BENZO[b][1,4]DIAZEPIN-2-IL)-BENZONITRILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE GLUTAMATO METABOTROPICO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ALZHEIMER, TRASTORNOS COGNITIVOS, DEFICITS DE MEMORIA, PSICOSIS, ESQUIZOFRENIA
PE2000001083A 1999-10-15 2000-10-10 Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico PE20010681A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99120520 1999-10-15

Publications (1)

Publication Number Publication Date
PE20010681A1 true PE20010681A1 (es) 2001-06-28

Family

ID=8239207

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001083A PE20010681A1 (es) 1999-10-15 2000-10-10 Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico

Country Status (35)

Country Link
US (1) US6407094B1 (es)
EP (1) EP1224174B1 (es)
JP (1) JP3857138B2 (es)
KR (1) KR100480320B1 (es)
CN (1) CN1195522C (es)
AR (1) AR026029A1 (es)
AT (1) ATE250039T1 (es)
AU (1) AU774451B2 (es)
BR (1) BR0014859A (es)
CA (1) CA2386974C (es)
CO (1) CO5261604A1 (es)
CZ (1) CZ20021653A3 (es)
DE (1) DE60005386T2 (es)
DK (1) DK1224174T3 (es)
EG (1) EG24079A (es)
ES (1) ES2204704T3 (es)
GC (1) GC0000263A (es)
HK (1) HK1051038A1 (es)
HR (1) HRP20020259A2 (es)
HU (1) HUP0203142A3 (es)
IL (2) IL148816A0 (es)
JO (1) JO2262B1 (es)
MA (1) MA26831A1 (es)
MY (1) MY125540A (es)
NO (1) NO327817B1 (es)
NZ (1) NZ517999A (es)
PE (1) PE20010681A1 (es)
PL (1) PL357418A1 (es)
PT (1) PT1224174E (es)
RU (1) RU2259360C2 (es)
SI (1) SI1224174T1 (es)
TR (1) TR200201023T2 (es)
WO (1) WO2001029011A2 (es)
YU (1) YU26202A (es)
ZA (1) ZA200202544B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1199954C (zh) 1999-10-15 2005-05-04 弗·哈夫曼-拉罗切有限公司 苯并二氮杂䓬衍生物
HUP0400991A3 (en) * 2001-04-12 2009-06-29 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them
CZ20033003A3 (cs) 2001-04-12 2004-05-12 F@Áhoffmann@Laárocheáag Dihydrobenzo [b][�Ź@]diazepin@onové deriváty jako MGLUR@ antagonisty II
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US8354447B2 (en) * 2002-09-10 2013-01-15 The Scripps Research Institute mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
BRPI0412919A (pt) * 2003-07-25 2006-09-26 Hoffmann La Roche combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
FR2862969A1 (fr) 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7459563B2 (en) 2004-11-05 2008-12-02 Hoffmann-La Roche Inc. Process for the preparation of isonicotinic acid derivatives
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
EP2137167B1 (en) * 2007-04-19 2011-08-10 F. Hoffmann-La Roche AG Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
TW200927731A (en) * 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
RU2488591C2 (ru) * 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Аналоги азацитидина и их применение
JP5433582B2 (ja) * 2007-11-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP5634506B2 (ja) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
EP2599775A4 (en) 2010-07-29 2014-04-30 Taisho Pharmaceutical Co Ltd ETHINYLPYRAZOLDERIVAT
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP2012153674A (ja) * 2011-01-28 2012-08-16 Astellas Pharma Inc ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US9895324B2 (en) 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
CA2950952C (en) 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法
CN109836356B (zh) * 2017-11-24 2022-03-08 沈阳化工研究院有限公司 一种芳甲醚衍生物及其应用
RU2702358C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов
CN114349779B (zh) * 2021-12-29 2023-09-26 智仑超纯环氧树脂(西安)有限公司 一种改性二氧化硅颗粒除氯剂及其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509847A (ja) * 1995-07-31 1999-08-31 ノボ ノルディスク アクティーゼルスカブ ヘテロ環式化合物、それらの調製及び使用
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂

Also Published As

Publication number Publication date
CN1379765A (zh) 2002-11-13
AR026029A1 (es) 2002-12-26
DE60005386D1 (de) 2003-10-23
KR20020038954A (ko) 2002-05-24
MY125540A (en) 2006-08-30
IL148816A0 (en) 2002-09-12
WO2001029011A2 (en) 2001-04-26
SI1224174T1 (en) 2003-12-31
CN1195522C (zh) 2005-04-06
HUP0203142A3 (en) 2003-03-28
EP1224174B1 (en) 2003-09-17
US6407094B1 (en) 2002-06-18
NO327817B1 (no) 2009-09-28
MA26831A1 (fr) 2004-12-20
JP3857138B2 (ja) 2006-12-13
PT1224174E (pt) 2004-01-30
YU26202A (sh) 2004-12-31
BR0014859A (pt) 2002-07-16
PL357418A1 (en) 2004-07-26
TR200201023T2 (tr) 2002-09-23
NO20021690L (no) 2002-04-10
NO20021690D0 (no) 2002-04-10
CA2386974C (en) 2009-10-13
CA2386974A1 (en) 2001-04-26
AU774451B2 (en) 2004-06-24
NZ517999A (en) 2004-07-30
CZ20021653A3 (cs) 2002-08-14
KR100480320B1 (ko) 2005-04-07
AU7910200A (en) 2001-04-30
IL148816A (en) 2006-10-31
CO5261604A1 (es) 2003-03-31
JO2262B1 (en) 2004-10-07
ATE250039T1 (de) 2003-10-15
JP2003512359A (ja) 2003-04-02
RU2259360C2 (ru) 2005-08-27
EG24079A (en) 2008-05-11
DK1224174T3 (da) 2004-01-26
DE60005386T2 (de) 2004-06-24
EP1224174A2 (en) 2002-07-24
HK1051038A1 (en) 2003-07-18
GC0000263A (en) 2006-11-01
HRP20020259A2 (en) 2004-04-30
HUP0203142A2 (hu) 2003-02-28
WO2001029011A3 (en) 2001-11-08
ZA200202544B (en) 2003-09-23
ES2204704T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
PE20010681A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20010759A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
PE20021041A1 (es) DERIVADOS DE DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-0NA COMO ANTAGONISTAS II mGLUR2
DK2803662T3 (en) P2X4 receptor antagonist
PE20010854A1 (es) USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1
PE20010467A1 (es) 1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20100741A1 (es) COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
PE20000170A1 (es) Derivados benzosulfonas
PE20060010A1 (es) 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C
JP2006522812A (ja) 複素環ｍｃｈｒ１アンタゴニスト
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
PE20001088A1 (es) Compuestos derivados de tetrahidrobenzazepina
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20050756A1 (es) Heterociclicos azabiciclicos como moduladores del receptor cannabinoide
PE20010574A1 (es) Derivados de indol como ligandos del receptor 5-ht2
EP3584237B1 (en) Alpha adrenergic receptor modulators
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE59999A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos
PE20011114A1 (es) Decahidro-isoquinolinas
PE20070122A1 (es) Proceso para preparar derivados de piperazina azindoloxoacetica sustituida con triazol y nuevas formas de sal producidas de los mismos
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed